CG Oncology, Inc. (CGON)
NASDAQ: CGON · Real-Time Price · USD
60.55
+2.79 (4.83%)
At close: Mar 3, 2026, 4:00 PM EST
60.78
+0.23 (0.38%)
After-hours: Mar 3, 2026, 4:19 PM EST
CG Oncology Stock Forecast
Stock Price Forecast
The 11 analysts with 12-month price forecasts for CG Oncology stock have an average target of 71.27, with a low estimate of 47 and a high estimate of 90. The average target predicts an increase of 17.70% from the current stock price of 60.55.
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for CG Oncology stock from 11 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Oct '25 | Nov '25 | Dec '25 | Jan '26 | Feb '26 | Mar '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 7 | 6 | 6 | 5 | 5 | 5 |
| Buy | 6 | 5 | 6 | 6 | 6 | 6 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 13 | 11 | 12 | 11 | 11 | 11 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Maintains $75 → $80 | Strong Buy | Maintains | $75 → $80 | +32.12% | Feb 27, 2026 |
| Truist Securities | Truist Securities | Strong Buy Maintains $66 → $75 | Strong Buy | Maintains | $66 → $75 | +23.86% | Feb 10, 2026 |
| RBC Capital | RBC Capital | Buy Maintains $61 → $73 | Buy | Maintains | $61 → $73 | +20.56% | Jan 21, 2026 |
| Piper Sandler | Piper Sandler | Buy Maintains $55 → $70 | Buy | Maintains | $55 → $70 | +15.61% | Jan 16, 2026 |
| Truist Securities | Truist Securities | Strong Buy Maintains $62 → $66 | Strong Buy | Maintains | $62 → $66 | +9.00% | Jan 12, 2026 |
Financial Forecast
Revenue This Year
33.69M
from 4.04M
Increased by 733.79%
Revenue Next Year
120.91M
from 33.69M
Increased by 258.94%
EPS This Year
-2.66
from -2.08
EPS Next Year
-2.36
from -2.66
Revenue Forecast
| Revenue | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| High | 116.5M | 275.4M | |||
| Avg | 33.7M | 120.9M | |||
| Low | n/a | 24.5M |
Revenue Growth
| Revenue Growth | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| High | 2,783.7% | 717.5% | |||
| Avg | 733.8% | 258.9% | |||
| Low | - | -27.3% |
EPS Forecast
| EPS | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| High | -1.43 | -0.74 | |||
| Avg | -2.66 | -2.36 | |||
| Low | -3.26 | -3.23 |
EPS Growth
| EPS Growth | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| High | - | - | |||
| Avg | - | - | |||
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.